Article info
PDFBasic and translational research
Concise report
Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis
- Correspondence to Professor Aline Bozec or Georg Schett, Department of Internal Medicine 3 and Institute of Clinical Immunology, University of Erlangen-Nuremberg, Erlangen 91054, Germany; aline.bozec{at}uk-erlangen.de or georg.schett{at}uk-erlangen.de
Citation
Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis
Publication history
- Accepted April 14, 2013
- First published May 10, 2013.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/